Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)
Forecasted
NIMH will fund a research network to study the real-world effectiveness, safety, and implementation of rapid-acting psychotropic drugs like ketamine and psilocybin for serious mental illnesses.
Funder: National Institutes of Health
Due Dates (Anticipated): November 2026 (projected)
Funding Amounts: Estimated total program funding: $20,000,000; approximately 3 awards expected; typical project period and award size not specified.
Summary: Supports a research network to generate real-world evidence on the effectiveness, safety, and implementation of rapid-acting psychotropic interventional drugs (RAPIDs) for serious mental illnesses.
Key Information: This is a forecasted opportunity; all dates are projected and subject to change.
Description
This forecasted funding opportunity from the National Institute of Mental Health (NIMH) aims to support the development of a research network focused on rapid-acting psychotropic interventional drugs (RAPIDs), such as ketamine, esketamine, psilocybin, and other emerging treatments for serious mental illnesses. While preliminary studies have shown that RAPIDs can result in significant improvements in mental health, there remain critical questions about their effectiveness, safety, durability of benefit, and best practices for implementation in real-world clinical settings.
The primary goal is to generate actionable, real-world evidence on the clinical effectiveness, safety, and implementation of these interventions, thereby informing future integration of RAPIDs into standard clinical care for diverse patient populations.
